Literature DB >> 11073565

Peritoneal dialysis in the next millennium.

D G Oreopoulos1, A H Tzamaloukas.   

Abstract

The main thrust of research will be the prevention of renal disease and its progression to the end-stage state (ESRD); such efforts will reduce or even reverse the present epidemic of ESRD by the middle of the 21(st) Century. In the meantime, the number of ESRD patients will continue to increase and, unless xenotransplantation and cloning of one's own kidneys using stem cells will provide an alternative, the various modes of dialysis will continue to be the principle treatment for an increasing numbers of ESRD patients. Peritoneal dialysis (PD) has achieved success at certain salient points and, to advance further, the next generation of nephrologists will have to build on these. They include the following: PD is the treatment of choice for children; it has low rates of peritonitis; it has similar (or in some countries, better) survival rates than hemodialysis; it has lower costs; it has adequate clearances through the introduction of automated PD; and it is an effective treatment for those awaiting a kidney transplant. This report presents the authors' views concerning the areas in which PD will improve in the future. These include (1) a reduction in technique failure rates that will allow us to maintain a larger number of patients on PD for 10 years or more; (2) prevention of long-term changes of the peritoneal membrane through the use of more "friendly" solutions; (3) prevention of malnutrition; (4) the development of better peritoneal access devices; and (5) the increased use of PD as the treatment of first choice for most ESRD patients. Copyright 2000 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 11073565     DOI: 10.1053/jarr.2000.18039

Source DB:  PubMed          Journal:  Adv Ren Replace Ther        ISSN: 1073-4449


  6 in total

1.  Repeat peritonitis in peritoneal dialysis: retrospective review of 181 consecutive cases.

Authors:  Cheuk-Chun Szeto; Bonnie Ching-Ha Kwan; Kai-Ming Chow; Man-Ching Law; Wing-Fai Pang; Chi-Bon Leung; Philip Kam-Tao Li
Journal:  Clin J Am Soc Nephrol       Date:  2010-12-23       Impact factor: 8.237

2.  Roles of neutrophil gelatinase-associated lipocalin in continuous ambulatory peritoneal dialysis-related peritonitis.

Authors:  Joseph C K Leung; Man Fai Lam; Sydney C W Tang; Loretta Y Y Chan; K Y Tam; Terence P S Yip; Kar Neng Lai
Journal:  J Clin Immunol       Date:  2009-01-16       Impact factor: 8.317

3.  Coagulase negative staphylococcal peritonitis in peritoneal dialysis patients: review of 232 consecutive cases.

Authors:  Cheuk-Chun Szeto; Bonnie Ching-Ha Kwan; Kai-Ming Chow; Miu-Fong Lau; Man-Ching Law; Kwok-Yi Chung; Chi-Bon Leung; Philip Kam-Tao Li
Journal:  Clin J Am Soc Nephrol       Date:  2007-11-21       Impact factor: 8.237

4.  Clinical and microbiological characteristics of peritoneal dialysis-related peritonitis caused by Escherichia coli in southern Taiwan.

Authors:  Wei-Hung Lin; Chin-Chung Tseng; An-Bang Wu; Yu-Tzu Chang; Te-Hui Kuo; Jo-Yen Chao; Ming-Cheng Wang; Jiunn-Jong Wu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-21       Impact factor: 3.267

Review 5.  Change in bacterial aetiology of peritoneal dialysis-related peritonitis over 10 years: experience from a centre in South-East Asia.

Authors:  C-C Szeto; C-B Leung; K-M Chow; B C-H Kwan; M-C Law; A Y-M Wang; S-F Lui; P K-T Li
Journal:  Clin Microbiol Infect       Date:  2005-10       Impact factor: 8.067

6.  Peritoneal dialysis-related peritonitis caused by Pseudomonas species: Insight from a post-millennial case series.

Authors:  Wanhong Lu; Bonnie Ching-Ha Kwan; Kai Ming Chow; Wing-Fai Pang; Chi Bon Leung; Philip Kam-To Li; Cheuk Chun Szeto
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.